ArticleInfection and drug resistance2026
Macrolide Resistance of
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The COVID-19 pandemic and associated non-pharmaceutical interventions (NPIs) have profoundly altered the circulation patterns of respiratory pathogens globally. In the context of the relaxation of these measures, a marked resurgence of Patients and Methods: We conducted a retrospective analysis of 12,380 respiratory specimens from pediatric patients at Hangzhou Children's Hospital (March 2024 to December 2025). MP nucleic acid and the 23S rRNA A2063G/A2064G resistance mutations were detected using quantitative PCR. Positivity and resistance rates were analyzed across gender, age, care setting (inpatient/outpatient), and temporal dimensions. Results: The overall MP positivity rate was 19.98% (2,473/12,380). Among positive cases, 86.94% (2,150/2,473) carried resistance mutations-representing one of the highest resistance levels documented globally. Critically, outpatients exhibited significantly higher resistance rates than inpatients (92.13% vs 86.10%; χ Conclusion: This post-pandemic laboratory surveillance reveals alarmingly high and persistently elevated macrolide resistance in pediatric MP infections in Hangzhou, with significantly higher resistance burdens in outpatients. The universal high resistance across all pediatric ages-including infants-suggests widespread community circulation of resistant strains. These findings underscore the urgent need for rapid resistance testing and antimicrobial stewardship programs specifically targeting outpatient pediatric settings in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.